Form 4: ARS Pharmaceuticals' Chief Medical Officer Sarina Tanimoto Sells Shares Under 10b5-1 Plan

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, sold shares of common stock on October 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Sarina Tanimoto, the Chief Medical Officer of ARS Pharmaceuticals, sold shares of the company's common stock on October 15, 2024.
• The sales were executed under a Rule 10b5-1 trading plan established on March 31, 2023.
• A total of 99,950 shares were sold in multiple transactions at weighted average prices ranging from $14.8642 to $15.2539.
• Following the reported transactions, Tanimoto directly owns 3,407,847 shares of common stock.
• She also has indirect ownership through various trusts, including the Sarina Tanimoto Charitable Remainder UniTrust, the Lowenthal-Tanimoto Family Trust, and trusts held by her spouse.
• Tanimoto disclaims beneficial ownership of shares held by the Richard E. Lowenthal Charitable Remainder UniTrust.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock sales by an insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about transactions.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.

Stakeholder Impact

• The share sales could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates